Portugal

Portugal has emerged as a premier European destination for life sciences investment, blending a high-caliber biotechnology sector with world-class pharmaceutical manufacturing capabilities.

The nation is best known for its "Innovation-to-Market" pipeline, anchored by renowned academic research institutions such as the Champalimaud Foundation and the Gulbenkian Institute of Molecular Medicine.

Global industry leaders are increasingly attracted to Portugal's specialized CDMO and CRO services, particularly in complex small molecule manufacturing and antibody discovery.

The medical device industry in Portugal is also witnessing rapid expansion, driven by expertise in biomaterials, robotics and digital health solutions tailored for aging populations.

This robust healthcare innovation ecosystem is supported by a highly qualified workforce, placing Portugal 5th globally in the number of health researchers per capita.

Strategic hubs like Biocant Park and Lisbon's Health Cluster foster a dynamic biotech startup scene, which recently gained international spotlight during BIO-Europe Spring 2026.

With total sector exports reaching €5.6 billion across 186 markets, Portugal offers a stable, competitive environment for clinical trials and biopharmaceutical production.

From cutting-edge genomics to sustainable therapeutic development, the Portuguese life sciences landscape provides the infrastructure and talent necessary for scaling global healthcare breakthroughs.